ANI Pharmaceuticals, Inc. (ANIP) fair value analysis
Nasdaq · Updated 2026-10-19
ANIP price how computed
Forward Fair Value verdict
UndervaluedANIP is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $72.29
- Sector
- Healthcare
- 12-month range
- $70.16–$94.48
- Market cap
- $1.66B
- From 52-week high
- -23.5%
- Shares outstanding
- 23M
- Rank in Healthcare by discount to fair value
- #7 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
ANI Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and distributes generic and branded medications. The company operates primarily in the United States, focusing on products across various therapeutic areas including pain management, cardiovascular health, and other specialty pharmaceuticals.
ANIP currently ranks #7 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.66B
- P/E (trailing)
- 9x
- Revenue (TTM)
- $978M
- Net margin
- 10.8%
- EPS (TTM)
- $7.87
- Gross margin
- 62.4%
- Debt / equity
- 0.55
- Revenue growth (3-yr avg)
- 33.9%
- Shares outstanding
- 23M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $73.73
- 200-day average
- $78.04
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-06
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+9.0%)
2026-03 ▲ beat (+75.0%)
2025-12 ▲ beat (+14.2%)
2025-09 ▲ beat (+15.3%)
2025-06 ▲ beat (+26.8%)
2025-03 ▲ beat (+23.2%)
2024-12 ▼ miss (-287.5%)
2024-09 ▲ beat (+22.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 2 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $106
- Target vs last price
- +46.6%
What our data shows for ANIP
- Our model validated 17 trailing price-to-earnings windows for ANIP, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $70.16–$94.48.
- The 14-day relative strength index sits at a neutral 44.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ANIP
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ANIP news
TickrTrends' derived news-sentiment signal for ANIP is currently leaning positive, computed from recent coverage.
- ANI Pharmaceuticals (ANIP) Launches Generic Duloxetine Capsules Targeting $247M Market (gurufocus.com, 2026-10-19)
TickrTrends take: ANI Pharmaceuticals' launch of generic duloxetine capsules positions the company to capture a portion of a $247 million market opportunity in a therapeutic category with established demand. Given TickrTrends' undervalued assessment of ANIP, investors focused on valuation metrics should monitor whether this product launch translates into revenue growth and margin expansion that could support the current pricing relative to fundamentals. The success of this generic entry will be a key indicator of management's ability to execute on pipeline initiatives and drive shareholder value in the competitive generic pharmaceuticals space. - ANI Pharmaceuticals (ANIP) Insider Sale: General Counsel Meredith Cook Sells 500 Shares (gurufocus.com, 2026-10-14)
TickrTrends take: ANI Pharmaceuticals operates in the Healthcare sector where insider trading activity can provide signals about management's confidence in current valuations. The recent sale of 500 shares by General Counsel Meredith Cook occurs within a context where TickrTrends currently rates the stock as undervalued, suggesting a disconnect between the company's assessed intrinsic worth and its market price. Investors focused on valuation metrics should monitor whether insider transactions continue at these levels, as persistent selling could either indicate confidence that shares will remain accessible at reasonable prices or potentially challenge the undervalued assessment. - A Look at ANI Pharmaceuticals Inc (ANIP) After 3.7% Decline -- GF Value $100.29 vs Price $70.84 (gurufocus.com, 2026-10-13)
TickrTrends take: ANI Pharmaceuticals Inc operates in the Healthcare sector, and according to TickrTrends analysis, the stock is currently considered undervalued. The recent market decline has widened the gap between the GF Value estimate and the current trading price, which may be relevant for investors focused on valuation metrics. Observers of the stock should monitor whether this valuation gap reflects temporary market pressure or signals a sustained repricing of the company's fundamental value.
More ANIP news
- ANI Pharmaceuticals (ANIP) Reports Positive Phase 4 SYNCHRONICITY Trial Results for Iluvien (gurufocus.com, 2026-10-12)
- ANI Pharmaceuticals (ANIP) CFO Stephen Carey Sells 2,850 Shares as Stock Trades Below GF Value (gurufocus.com, 2026-09-30)
What people are saying
Follow the ANIP conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ANIP stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ANIP is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ANIP's TickrTrends verdict?
ANIP's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ANIP compare to other Healthcare stocks?
ANIP ranks #7 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ANIP overbought or oversold?
ANIP's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ANIP report earnings next?
ANIP's next earnings report is scheduled for 2026-11-06, per the published earnings calendar.
Does ANIP usually beat earnings estimates?
Over its last 8 reported quarters ANIP beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ANIP?
Of 9 analysts covering ANIP, 7 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $106 (+46.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ANIP vs ADMA · ANIP vs ALGN · ANIP vs ALNY · ANIP vs ASTH · ANIP vs AZN